or Try an Advanced Search...

    Technical Analysis for NUVB - Nuvation Bio Inc.

    Grade Last Price % Change Price Change
    C 3.16 8.22% 0.24
    NUVB closed up 8.22 percent on Monday, July 1, 2024, on 1.46 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    Earnings due: Jul 10
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical NUVB trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Centerline Cross Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Gapped Up Strength 0.00%
    Fell Below 20 DMA Bearish 8.22%
    Fell Below 50 DMA Bearish 8.22%
    Expansion Pivot Sell Setup Bearish Swing Setup 8.22%
    Volume Surge Other 8.22%
    Older End-of-Day Signals for NUVB ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 7 hours ago
    Up 1 ATR about 7 hours ago
    Rose Above 50 DMA about 10 hours ago
    10 DMA Support about 10 hours ago
    Rose Above 10 DMA about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    NUVB Chart by TradingView
    Basic chart:

    Profile

    Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Prostate Cancer

    Is NUVB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 20 Nuvation Bio: A Potentially Transformative Acquisition
    Jun 1 Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
    May 29 Nuvation Bio to Present at the Jefferies Global Healthcare Conference
    May 15 Nuvation Bio GAAP EPS of -$0.07
    May 14 Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
    Apr 24 Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 10 Nuvation Bio Completes Acquisition of AnHeart Therapeutics
    Mar 31 Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
    Mar 28 Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
    Mar 27 Nuvation Bio continues to surge as more upgrades follow after AnHeart deal
    See more NUVB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.1598
    52 Week Low 0.95
    Average Volume 1,603,275
    200-Day Moving Average 2.05
    50-Day Moving Average 3.03
    20-Day Moving Average 2.93
    10-Day Moving Average 3.01
    Average True Range 0.21
    RSI (14) 56.33
    ADX 18.25
    +DI 24.01
    -DI 16.67
    Chandelier Exit (Long, 3 ATRs) 2.64
    Chandelier Exit (Short, 3 ATRs) 3.19
    Upper Bollinger Bands 3.18
    Lower Bollinger Band 2.67
    Percent B (%b) 0.96
    BandWidth 17.26
    MACD Line 0.01
    MACD Signal Line -0.01
    MACD Histogram 0.0196
    Fundamentals Value
    Market Cap 688.7 Million
    Num Shares 218 Million
    EPS -0.37
    Price-to-Earnings (P/E) Ratio -8.54
    Price-to-Sales 0.00
    Price-to-Book 0.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.58
    Resistance 3 (R3) 3.53 3.35 3.51
    Resistance 2 (R2) 3.35 3.24 3.37 3.49
    Resistance 1 (R1) 3.25 3.17 3.30 3.30 3.46
    Pivot Point 3.07 3.07 3.09 3.09 3.07
    Support 1 (S1) 2.97 2.96 3.02 3.02 2.86
    Support 2 (S2) 2.79 2.89 2.81 2.83
    Support 3 (S3) 2.69 2.79 2.81
    Support 4 (S4) 2.74